Global Bone Marrow Transplant Market, by Type (Autologous Transplant, Allogeneic Transplant, and Others), by Treatment Type (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, and Others), by End User (Hospitals, Multi-specialty Clinics, and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 10,356.1 Million in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research activities by key players to develop a drug that can prevent the complications associated with post bone marrow transplant is expected to drive the market growth over the forecast period. For instance, in May 2020, Gamida Cell, a leader in the development of stem cell therapy technologies and products, announced positive topline results from the Phase 3 trials of a clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant. A bone marrow transplant is not always effective and can lead to serious complications such as graft-versus-host disease, organ damage, infections, etc. The drug is intended to address the current limitations of bone marrow transplant by providing a therapeutic dose of stem cells while preserving the cells’ functional therapeutic characteristics.
Global Bone Marrow Transplant Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
The COVID-19 pandemic had a negative impact on the bone marrow transplant market, owing to the lockdown and thereby decreased number of bone marrow donors. For instance, according to an article published by Springer Nature Limited, a global publisher, in October 2021, national lockdown, international frontiers closing, flight and train circulation restrictions were established internationally to control COVID-19 spread, making it more challenging to procure stem cells from international and national donors. According to the same source, a study was carried out to review the impact of the COVID-19 pandemic on the collection and utilization of unrelated umbilical cord blood units (UCB) facilitated by the French Cord Blood Banks (CBB) Network during 2020 in comparison to 2019. According to the results, from January to December 2020, 4,392 UCBs were collected by the French CBB Network, compared to 7,989 units in 2019, which was a 45% decrease in the collection activity in 2020.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Bone Marrow Transplant Market”- Forecast to 2030, Global Bone Marrow Transplant Market, by Type (Autologous Transplant, Allogenic Transplant, and Others), by Treatment Type (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, and Others), by End User (Hospitals, Multi-specialty Clinics, and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Bone Marrow Transplant Market, click the link below:
Moreover, increasing research activities of bone marrow transplants is expected to drive the market growth over the forecast period. For instance, according to an article published by the Boston University School of Medicine, a research institution, in March 2022, the findings of a research study led by the researchers at Boston University School of Medicine and Massachusetts General Hospital (MGH), having the largest hospital based research program in the U.S., revealed the unique signature of genes expressed by hematopoietic stem cells (HSCs) is capable of undergoing engraftment. The study revealed that these stem cells express a protein on their surface called CD201 that correlates very closely with the engraftment potential and can be used to isolate functional stem cells away from other cell types. This can help to improve the process of bone marrow and stem cell transplantation by allowing the purification of these cells.
Key Takeaways of the Global Bone Marrow Transplant Market: